This inventor holds 1 USPTO granted patent and 6 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignee: Actinium Pharmaceuticals, Limited. Active years: 2024.
Company Filing History:
Years Active: 2024
Title: Keisha Thomas: Innovator in Gene-Edited Cell Therapies
Introduction
Keisha Thomas is a prominent inventor based in Brooklyn, NY. She has made significant contributions to the field of gene-edited cell therapies. Her innovative work focuses on methods that enhance the treatment of non-cancerous disorders.
Latest Patents
Keisha Thomas holds a patent for her invention titled "Anti-CD45-based conditioning methods and uses thereof in conjunction with gene-edited cell-based therapies." This invention provides a method for depleting a subject's hematopoietic stem cells by administering an effective amount of a radiolabeled anti-CD45 antibody, such as I-BC8 or Ac-BC8. Additionally, it outlines a method for treating subjects afflicted with non-cancerous disorders through genetically edited cell therapy. This involves administering a radiolabeled anti-CD45 antibody to deplete hematopoietic stem cells, followed by therapy to address the subject's disorder. The invention also includes articles of manufacture for performing these methods.
Career Highlights
Keisha Thomas is currently associated with Actinium Pharmaceuticals, Limited, where she continues to advance her research and innovations. Her work is pivotal in the development of therapies that utilize gene editing to improve patient outcomes.
Collaborations
Keisha collaborates with notable colleagues, including Mark Berger and Sandesh Seth, who contribute to her research endeavors and the advancement of their shared goals in the field of biotechnology.
Conclusion
Keisha Thomas exemplifies the spirit of innovation in the realm of gene-edited therapies. Her contributions are paving the way for new treatment methodologies that hold promise for patients with non-cancerous disorders.